AstraZeneca - NewsroomPost

AstraZeneca reaffirms vaccine safety amidst rare side effect concerns

AstraZeneca reaffirms vaccine safety amidst rare side effect concerns

ANI

India records 2,17,353 new Covid-19 cases and 1,185 deaths in 24 hrs, highest single-day spike

India records 2,17,353 new Covid-19 cases and 1,185 deaths in 24 hrs, highest single-day spike

Newsroom Staff

So far, 68 countries received COVID-19 vaccines manufactured in India: MEA

So far, 68 countries received COVID-19 vaccines manufactured in India: MEA

Newsroom Staff

Vaccines approved are ‘110 % safe,’ says DCGI Chief VG Somani

Vaccines approved are ‘110 % safe,’ says DCGI Chief VG Somani

Newsroom Staff

India approves coronavirus vaccine developed by AstraZeneca and Oxford University

India approves coronavirus vaccine developed by AstraZeneca and Oxford University

Newsroom Staff

Covid-19 vaccine: SII’s Covishield approved by expert panel for emergency use

Covid-19 vaccine: SII’s Covishield approved by expert panel for emergency use

Newsroom Staff

India closer to Covid-19 vaccine, Drug Controller hints for approval

India closer to Covid-19 vaccine, Drug Controller hints for approval

Newsroom Staff

Serum Institute of India to apply for emergency use of vaccine in 2 weeks

Serum Institute of India to apply for emergency use of vaccine in 2 weeks

Newsroom Staff

PM Modi visits Zydus Biotech Park in Ahmedabad, reviews vaccine development

PM Modi visits Zydus Biotech Park in Ahmedabad, reviews vaccine development

Newsroom Staff

Oxford-AstraZeneca vaccine met primary efficacy endpoint, can be 90% effective, results show

Oxford-AstraZeneca vaccine met primary efficacy endpoint, can be 90% effective, results show

Newsroom Staff

© 2024, All Rights Reserved by Headlong Newsroom Post India Private Limited